



# Lassa Fever Situation Report

Epi Week 17: 21<sup>st</sup> – 27<sup>th</sup> April 2025

## Key Points

**Table 1: Summary of the current week (17), cumulative Epi week 17, 2025 and comparison with the previous year (2024)**

Reporting Period	Suspected cases	Confirmed cases	Probable cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States and LGAs affected (Confirmed cases)
<b>Current week</b> (week 17)	160	11	0	3	27.3%	State(s):4 LGA(s): 8
<b>2025 Cumulative</b> (week 17)	4672	707	7	135	19.1%	State(s):18 LGA(s): 93
<b>2024 Cumulative</b> (week 17)	6106	869	17	156	18.0%	State(s):28 LGA(s): 124

## Highlights

- In week 17, the number of new confirmed cases increased from 10 in epi week 16, of 2025 to 11. These were reported in Ondo, Bauchi, Taraba, and Edo States (Table 3)
- Cumulatively in week 17, 2025, 135 deaths have been reported with a Case Fatality Rate (CFR) of 19.1% which is higher than the CFR for the same period in 2024 (18.0%)
- In total for 2025, 18 States have recorded at least one confirmed case across 93 Local Government Areas (Figures 2 and 3)
- Seventy-one (71%) of all confirmed Lassa fever cases were reported from three states (Ondo, Bauchi and Taraba) while 28% were reported from 15 states with confirmed Lassa fever cases. Of the 71% confirmed cases, Ondo reported 30%, Bauchi 25%, and Taraba 16%
- The predominant age group affected is 21-30 years (Range: 1 to 96 years, Median Age: 30 years). The male-to-female ratio for confirmed cases is 1:0.8 (Figure 4)
- The number of suspected cases decreased compared to that reported for the same period in 2024.
- One new healthcare worker was affected in the reporting week 17.
- National Lassa fever multi-partner, multi-sectoral Incident Management System (IMS) activated to coordinate the response activities at all levels.




Figure 1. Confirmed Lassa Fever Cases in Nigeria Epidemiological Week 17, 2025




Figure 2. Confirmed Lassa fever cases by States in Nigeria, week 17, 2025




Figure 3. Confirmed Lassa fever attack rate per 100,000 population for LGAs in Nigeria, week 17, 2025

Table 2: Key indicators for the current week in 2025 and trend compared to the previous week, Nigeria

Symptomatic contacts	Number for current week	Trend from previous week	Cumulative number for 2025
Probable cases	0	↔	7
Health Care Worker affected	1	↑	22
Cases managed at the treatment centres	8	↑	576
<b>Contact tracing</b>			
Cumulative contact listed	0	↔	3200
Contacts under follow up	215	↓	215
Contacts completed follow up	20	↓	1448
Symptomatic contacts	0	↔	15
Positive contacts	0	↔	15
Contacts lost to follow up	0	↔	0



Key

↑ Increase  
 ↓ Decrease  
 ↔ No difference

**Epi Week: 17 2025**

**Table 3. Weekly and Cumulative number of suspected and confirmed cases for 2025**

	States	Current week: (Week 17 )							Cumulative (Week 1 - 17 )				
		Cases					Deaths (Confirmed Cases)	Cases				Deaths (Confirmed Cases)	
		Suspected	Confirmed	Trend	Probable	HCW*		Suspected	Confirmed	Probable	HCW*		
1	Ondo	49	4	▲					1436	211		8	27
2	Bauchi	25	3	▲				1	798	179	1	4	14
3	Taraba	14	2	▼				1	313	116		3	34
4	Edo	47	2	▲		1		1	1346	110		2	18
5	Ebonyi	15							212	21		1	11
6	Kogi	1							66	15			4
7	Gombe								69	14	1	2	7
8	Plateau								51	13	1		5
9	Benue								63	9	4	1	4
10	Nasarawa	2							73	5			4
11	Kaduna	1							21	3			2
12	Enugu	1							20	3			1
13	Delta	1							20	2			2
14	Cross River								30	2			1
15	Borno	1							6	1			
16	Ogun								13	1			1
17	Fct								10	1		1	
18	Anambra	2							14	1			
19	Osun								1				
20	Katsina								1				
21	Kwara								3				
22	Jigawa								1				
23	Yobe								4				
24	Akwa Ibom								2				
25	Niger								2				
26	Ekiti								20				
27	Rivers	1							11				
28	Adamawa								9				
29	Abia								7				
30	Imo								5				
31	Bayelsa								2				
32	Oyo								24				
33	Lagos								11				
34	Kano								8				
	Total	160	11	▲		1		3	4672	707	7	22	135

<b>Key</b>	
	Decrease
	Increase




Figure 4. Age and sex pyramid showing the number of confirmed Lassa fever cases for 2025




Figure 5: Number of confirmed cases with Case Fatality Rate (CFR) by state week 17, 2025




Figure 6: Trend of confirmed cases by epidemiological week, 2021–2025, Nigeria



- Printed and disseminated copies of IPC Viral Hemorrhagic Fever (VHF) guidelines to health facilities with support from Robert Koch Institute
- Supported State IPC structures, the Orange Network, and treatment centers to enforce standard precautions to reduce Hospital-Acquired Infections (HAIs) in high-burden LGAs and States
- Held an orientation on the Lassa fever Advocacy toolkit for NRRT Deployment/Frontliners with support from BA-N
- Shared resources materials to reporting and non-reporting States and the FCT e.g. Public and Healthcare worker's advisories etc.
- Deployed 10 National Rapid Response Teams to 10 states to support onsite control and management efforts using a One Health approach
- Held a seven part webinar series in readiness for the 2024/2025 outbreak season
- Participated in the official handing over of laboratory equipment by IHVN to the Ondo State Public Health laboratory
- Held bilateral discussions with MSF Geneva on mutual areas of collaboration for Lassa fever
- Identified areas of mutual collaboration with Nigeria Health Watch
- Conducted a webinar on geospatial risk mapping tool
- Treatment of confirmed cases at identified treatment centres across the states and the FCT
- HCWs trained on case management in Bauchi, Ebonyi & Benue states with the support of WHO
- Participated in the Regional Training on Lassa Fever Clinical Management in ECOWAS Countries in Togo
- Held bilateral meeting with WHO HQ on areas of mutual collaboration
- Conducted the 3rd Monthly Webinar Series on Lassa fever Clinical Management (focused on what HCWs should know)- initiated by Georgetown University & its local affiliate
- Disseminated the reviewed IPC guidelines, health facility IPC advisory and healthcare worker advisories
- Held the Global IPC Survey in collaboration with WHO
- Conducted the IPC Guideline development workshop in Bauchi State supported by WB through CoPREP
- Analysed samples across the Laboratory network for Lassa fever to guide prompt diagnosis and treatment
- Conducted a needs assessment across the designated LF Treatment Centres (TCs)
- Scheduled regular External Quality Assurance (EQA) for all testing laboratories
- Forecasted and quantified Medical Countermeasures (MCMs) for Lassa fever
- Distributed response commodities -PPEs, Ribavirin (injection and tablets) body-bags, thermometers, hypochlorite hand sanitizers, and IEC materials distributed to states and treatment centres
- Developed a distribution and prepositioning plan of Lassa Fever Commodities
- Flagged off the Nigeria Lassa fever epidemiological Study (ENABLE 1.5) supported by CEPI
- Conducted the first round of quarterly participants follow-up and blood sampling exercise at FMCO, ISTH and AEFUTHA sites
- Held the baseline audiometry assessment for FMCO and ISTH sites (ENABLE 1.5)
- Supported the protocol development for Community-Based One Health Participatory and Empowerment Strategy (COPE II)
- Completed the first phase of intervariability analysis for Enable 1.5 study
- Commenced the second Phase of Inter-assay testing of Enable 1.0 samples
- Conducted the first round of monthly participants' follow-up and blood sampling exercise for quarter one
- Disseminated media contents including press releases, tweets, public advisories etc
- Sensitized healthcare workers and other community structures across hotspot LGAs
- Collaborated with BA-N to review and validate the Lassa Fever advocacy toolkit
- Developed a targeted communication strategy based on the data from the community survey conducted in 3 states
- Participated in a three-day workplan development workshop supported by UNICEF
- Leveraged on partners and stakeholders media platforms to disseminate LF message
- Updated the VHF Case Investigation Form (CIF) database
- Enhanced surveillance (contact tracing and active case finding) in affected states
- Monitored the outbreak emergency composite indicators to guide timely decision making
- Held a meeting with partners to identify priority support areas for the pillar
- Activated Multi-sectoral Incident Management System for Public Health Emergency Operation Centres (PHEOC) in affected States
- Developed and disseminated SMS on LF with the support of Breakthrough Action Nigeria (BA-N) in Benue State
- Supported ongoing active case search in Ondo State's health facilities and communities, in collaboration with IHVN
- Held a Multi-Sectoral Health Promotion, Communication, and Disease Prevention Capacity Building workshop on Risk Communication and Community Engagement in Cross River State supported by Nigeria Health Watch

- Conducted a multi-sectoral capacity building on health promotion, risk communication, and community engagement for disease prevention in Cross River State, with support from Nigeria Health Watch
- Facilitated Lassa fever sensitization at Glo 99.1 FM, Ondo state
- Supervised Community sensitization in Owo, Ondo State
- Held a Training of Trainers (ToT) workshop of One Health partners on rodent control and Lassa fever prevention collaboration with BA-N
- Implemented Lassa fever Environmental response campaign in high-burden states

## Challenges

- Late presentation of cases leading to an increase in CFR
- Poor health-seeking behaviour due to the high cost of treatment and clinical management of Lassa fever
- Poor environmental sanitation conditions observed in high-burden communities
- Poor awareness observed in high-burden communities

## Notes on this report

### Data Source

Information for this disease was case-based data retrieved from the National Lassa Fever Technical Working Group.

### Case definitions

- **Suspected case:** any individual presenting with one or more of the following: malaise, fever, headache, sore throat, cough, nausea, vomiting, diarrhoea, myalgia, chest pain, hearing loss and either a. History of contact with excreta or urine of rodents b. History of contact with a probable or confirmed Lassa fever case within a period of 21 days of onset of symptoms OR Any person with inexplicable bleeding/haemorrhage.
- **Confirmed case:** any suspected case with laboratory confirmation (positive IgM antibody, PCR or virus isolation)
- **Probable case:** any suspected case (see definition above) who died or absconded without collection of specimen for laboratory testing
- **Contact:** Anyone who has been exposed to an infected person, or to an infected person's secretions, excretions, or tissues within three weeks of last contact with a confirmed or probable case of Lassa fever

### Calculations

- Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.

### VIRAL HAEMORRHAGIC FEVER QUICK REFERENCE GUIDE

For social mobilization [https://ncdc.gov.ng/themes/common/docs/vhfs/83\\_1517222929.pdf](https://ncdc.gov.ng/themes/common/docs/vhfs/83_1517222929.pdf)

For LGA Rapid Response Team [https://ncdc.gov.ng/themes/common/docs/vhfs/82\\_1517222811.pdf](https://ncdc.gov.ng/themes/common/docs/vhfs/82_1517222811.pdf)

Healthcare worker laboratory [https://ncdc.gov.ng/themes/common/docs/vhfs/81\\_1517222763.pdf](https://ncdc.gov.ng/themes/common/docs/vhfs/81_1517222763.pdf)

For healthcare workers [https://ncdc.gov.ng/themes/common/docs/vhfs/80\\_1517222586.pdf](https://ncdc.gov.ng/themes/common/docs/vhfs/80_1517222586.pdf)

For community informants [https://ncdc.gov.ng/themes/common/docs/vhfs/79\\_1517222512.pdf](https://ncdc.gov.ng/themes/common/docs/vhfs/79_1517222512.pdf)

### NATIONAL GUIDELINES FOR LASSA FEVER CASE MANAGEMENT

[https://ncdc.gov.ng/themes/common/docs/protocols/92\\_1547068532.pdf](https://ncdc.gov.ng/themes/common/docs/protocols/92_1547068532.pdf)

### VIRAL HAEMORRHAGIC FEVER AND RESPONSE PLAN

[https://ncdc.gov.ng/themes/common/docs/protocols/24\\_1502192155.pdf](https://ncdc.gov.ng/themes/common/docs/protocols/24_1502192155.pdf)

### NATIONAL GUIDELINE FOR INFECTION, PREVENTION AND CONTROL FOR VIRAL HAEMORRHAGIC FEVER INFORMATION RESOURCE

[https://ncdc.gov.ng/themes/common/docs/protocols/341\\_1707300274.pdf](https://ncdc.gov.ng/themes/common/docs/protocols/341_1707300274.pdf)

Nigeria Centre for Disease Control and Prevention: [www.ncdc.gov.ng](http://www.ncdc.gov.ng)

**Disclaimer** – This situation report is based on the best available information reported. The NCDC is not responsible for information shared with third parties or any interpretation outside what is published. The report may not be used, published, or redistributed to the public. All redacted Lassa fever situation reports are available at <http://ncdc.gov.ng/diseases/sitreps>